MXCT vs. MGTX, OABI, ABSI, HBIO, NOTV, ANIK, TCRX, SKIN, BVS, and TRML
Should you be buying MaxCyte stock or one of its competitors? The main competitors of MaxCyte include MeiraGTx (MGTX), OmniAb (OABI), Absci (ABSI), Harvard Bioscience (HBIO), Inotiv (NOTV), Anika Therapeutics (ANIK), TScan Therapeutics (TCRX), Beauty Health (SKIN), Bioventus (BVS), and Tourmaline Bio (TRML).
MeiraGTx (NASDAQ:MGTX) and MaxCyte (NASDAQ:MXCT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, community ranking, risk and earnings.
In the previous week, MaxCyte had 4 more articles in the media than MeiraGTx. MarketBeat recorded 12 mentions for MaxCyte and 8 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.82 beat MaxCyte's score of -0.32 indicating that MaxCyte is being referred to more favorably in the news media.
MeiraGTx has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500. Comparatively, MaxCyte has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
MaxCyte has a net margin of -83.00% compared to MaxCyte's net margin of -651.19%. MeiraGTx's return on equity of -15.68% beat MaxCyte's return on equity.
MeiraGTx received 176 more outperform votes than MaxCyte when rated by MarketBeat users. However, 84.62% of users gave MaxCyte an outperform vote while only 71.10% of users gave MeiraGTx an outperform vote.
MeiraGTx presently has a consensus target price of $25.67, indicating a potential upside of 406.25%. MaxCyte has a consensus target price of $8.67, indicating a potential upside of 82.84%. Given MaxCyte's higher possible upside, equities analysts clearly believe MeiraGTx is more favorable than MaxCyte.
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 68.8% of MaxCyte shares are held by institutional investors. 9.7% of MeiraGTx shares are held by company insiders. Comparatively, 6.0% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
MaxCyte has higher revenue and earnings than MeiraGTx. MaxCyte is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.
Summary
MaxCyte beats MeiraGTx on 12 of the 17 factors compared between the two stocks.
Get MaxCyte News Delivered to You Automatically
Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MXCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
